Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Etoricoxib vs Arcoxia 120 mg in Healthy Volunteers
NCT04830579Phase 1Unknown
- Sponsor
- Pharmtechnology
- Start
- Apr 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of etoricoxib in acute gouty arthritis, osteoarthritis (OA), rheumatoid arthritis (RA) and 1 more (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Last Timepoint. Status: unknown.
02
Drugs
etoricoxib
03
Conditions
acute gouty arthritisosteoarthritis (OA)rheumatoid arthritis (RA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04830579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830579.